Oral glucocorticoids for skin fibrosis in early diffuse systemic sclerosis: a target trial emulation study from the European Scleroderma Trials and Research group database
Denis Mongin,Marco Matucci-Cerinic,Ulrich A Walker,Oliver Distler,Radim Becvar,Elise Siegert,Lidia P Ananyeva,Vanessa Smith,Juan Jose Alegre-Sancho,Sule Yavuz,Massimiliano Limonta,Gabriela Riemekasten,Elena Rezus,Madelon Vonk,Marie-Elise Truchetet,Francesco Del Galdo,Delphine S Courvoisier,Michele Iudici,EUSTAR collaborators,Florenzo Iannone,Otylia Kowal Bielecka,Carmen Pizzorni,Francesco Ciccia,Simona Rednic,P Vlachoyiannopoulos,Jiri Stork,Murat Inanc,Patricia E Carreira,Srdan Novak,Laszlo Czirjak,Eugene J Kucharz,Katja Perdan-Pirkmajer,Bernard Coleiro,Gianluca Moroncini,Dominique Farge Bancel,Fabian A Mendoza,Roger Hesselstrand,Mislav Radic,Alexandra Balbir-Gurman,Andrea Lo Monaco,Raffaele Pellerito,Alessandro Giollo,Jadranka Morovic-Vergles,Christopher Denton,Nemanja Damjanov,Jörg Henes,Vera Ortiz Santamaria,Stefan Heitmann,Dorota Krasowska,Paul Hasler,Barbara Russo,Michaela Kohm,Ivan Foeldvari,Gianluigi Bajocchi,Maria Joao Salvador,Bojana Stamenkovic,Carlo Francesco Selmi,Mohammed Tikly,Ariane Herrick,Ulf Muller-Ladner,Klaus Søndergaard,Francesco Puppo,Merete Engelhart,Gabriela Szucs,Carlos de la Puente,Valeria Riccieri,Ruxandra Maria Ionescu,Ami Sha,Ana Maria Gheorghiu,Cord Sunderkötter,Joörg Distler,Francesca Ingegnoli,Luc Mouthon,Francesco Paolo Cantatore,Susanne Ullman,Carlos Alberto von Muhlen,Maria Rosa Pozzi,Kilian Eyerich,Piotr Wiland,Marie Vanthuyne,Kristine Herrmann,Ellen De Langhe,Branimir Anic,Marko Baresic,Miroslav Mayer,Maria Uprus,Kati Otsa,Brigitte Granel,Carolina de Souza Muller,Svetlana Agachi,Simon Stebbings,Alessandro Mathieu,Alessandra Vacca,Percival D Sampaio-Barros,Lisa Stamp,Kamal Solanki,Douglas Veale,Esthela Loyo,Carmen Tineo,Walid Ahmed Abdel Atty Mohamed,Jacek Olas,Fahrettin Oksel,Figen Yargucu,Cristina-Mihaela Tanaseanu,Rosario Foti,Codrina Ancuta,Daniel E Furst,Britta Maurer,Jacob van Laar,Marzena Olesinska,Cristiane Kayser,Nihal Fathi,Paloma Garcıa de la Pena Lefebvre,Jorge Juan Gonzalez Martin,Patrick Carpentier,Bernard Imbert,Camille Frances,Patricia Senet,Jean Sibilia,Ira Litinsky,Jean Luc Senecal,Martial Koenig,France Joval,Grodzicky Tamara,Goda Seskute,Lesley Ann Saketkoo,Eduardo Kerzberg,Washington Bianchi,Breno Valdetaro Bianchi,Ivan Castellvı,Jasminka Milas-Ahic,Roberta Visevic,Francois Spertini,Antonella Marcoccia,Sarah Kahl,Vivien M Hsu,Thierry Martin,Sergey Moiseev,Pavel Novikov,Lorinda S Chung,Tim Schmeiser,Dominik Majewski,Zbigniew Zdrojewski,Julia MartınezBarrio,Dinesh Khanna,Vera Bernardino,Lelita Santo,Yair Levy,Omer Nuri Pamuk,Daniel Brito de Araujo,Piercarlo Sarzi Puttini,Marek Brzosko,Hadi Poormoghim,Marta Maman,Ina Kotter,Giovanna Cuomo,Francis Gaches,Laura Belloli,Petros Sfikakis,Juliana Markus,Daniel Furst,AnaMaria Ramazan,Patrick Jego,Lorenzo Dagna,J M van Laar,Lidia Rudnicka,Susana Oliveira,Fabiola Atzeni,Masataka Kuwana,Arsene Mekinian,Mickael Martin,Yoshiya Tanaka,Hidekata Yasuoka,Carmen-Pilar Simeon-Aznar,Tatsuya Atsumi,Magda Parvu,Ines Cordeiro,Nicoletta Del Papa,Thomas Karonitsch,Anna Bazela-Ostromecka,Enrico Selvi,Yasushi Kawaguchi,Tomas Soukup,Ignasi Rodriguez-Pinto,Marija Geroldinger-Simic,Gerard Espinosa,Karen Voigt,Torsten Kubacki,Olena Garmish,Marta Mosca,Ulrich Gerth,Ludmila Antonenko
DOI: https://doi.org/10.1002/acr.25469
2024-11-14
Abstract:Objectives: The objective of this study is to evaluate whether adding oral glucocorticoids to immunosuppressive therapy improves skin scores and ensures safety in patients with early diffuse cutaneous systemic sclerosis (dcSSc). Methods: We performed an emulated randomized trial comparing the changes from baseline to 12±3 months of the modified Rodnan skin score (mRSS: primary outcome) in early dcSSc patients receiving either oral glucocorticoids (≤20 mg/day prednisone-equivalent) combined with immunosuppression (treated), or immunosuppression alone (controls), using data from the European Scleroderma Trials and Research Group. Secondary endpoints were the difference occurrence of progressive skin or lung fibrosis, and scleroderma renal crisis. Matching propensity score was used to adjust for baseline imbalance between groups. Results: We matched 208 patients (age 49 years; 33% male; 59% anti-Scl70), 104 in each treatment group, obtaining comparable characteristics at baseline. In the treated group, patients received a median prednisone dose of 5 mg/day. Mean mRSS change at 12±3 months was similar in the two groups (decrease of 2.7 [95% CI 1.4 - 4.0] in treated vs. 3.1 [95% CI 1.9 - 4.4] in control, p = 0.64). Similar results were observed in patients with shorter disease duration (≤ 24 months) or with mRSS ≤22. There was no between-group difference for all prespecified secondary outcomes. A case of scleroderma renal crisis occurred in both groups. Conclusions: We did not find any significant benefit of adding low-dose oral glucocorticoids to immunosuppression for skin fibrosis, and at this dosage, glucocorticoid did not increase the risk of scleroderma renal crisis.